UY32308A - Nucleótidos uracil ciclopropílicos - Google Patents
Nucleótidos uracil ciclopropílicosInfo
- Publication number
- UY32308A UY32308A UY0001032308A UY32308A UY32308A UY 32308 A UY32308 A UY 32308A UY 0001032308 A UY0001032308 A UY 0001032308A UY 32308 A UY32308 A UY 32308A UY 32308 A UY32308 A UY 32308A
- Authority
- UY
- Uruguay
- Prior art keywords
- benzyl
- alkyl
- hydrogen
- cyclopropyll
- uracil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de fórmula I: que incluyen cualquier estereoisómero posible de los mismo, donde: R1 es hidrógeno o halo; R4 es un éster de monofosfato, difosfato o trifosfato; o R4 es un grupo de fórmula R7 e fenilo opcionalmente sustituido; naftilo, indolilo o N-alquiloxi C1-C6-carbonilindolilo; R8 es hidrógeno, alquilo C1-C6, bencilo; R8´ es hidrógeno, alquilo C1-C6, bencilo; o R8 y R8´ conjuntamente con el átomo de carbono al cual están unidos forman cicloalquilo C3-C7; R9 es alquilo C1-C10, bencilo, o fenilo opcionalmente sustituido; o una sal o solvato de los mismos. formulaciones farmacéuticas y el uso de compuestos I como inhibidores de HCV
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08171006 | 2008-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32308A true UY32308A (es) | 2010-06-30 |
Family
ID=40852521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032308A UY32308A (es) | 2008-12-08 | 2009-12-08 | Nucleótidos uracil ciclopropílicos |
Country Status (21)
Country | Link |
---|---|
US (1) | US8399429B2 (es) |
EP (1) | EP2373671B1 (es) |
JP (1) | JP5683480B2 (es) |
KR (1) | KR20110104000A (es) |
CN (1) | CN102256991B (es) |
AP (1) | AP2011005717A0 (es) |
AR (1) | AR074504A1 (es) |
AU (1) | AU2009326125B2 (es) |
BR (1) | BRPI0922681A2 (es) |
CA (1) | CA2745523C (es) |
CL (1) | CL2011001364A1 (es) |
EA (1) | EA020244B1 (es) |
ES (1) | ES2525007T3 (es) |
IL (1) | IL212897A (es) |
MX (1) | MX2011006023A (es) |
PA (1) | PA8852101A1 (es) |
SG (1) | SG171973A1 (es) |
TW (1) | TW201036989A (es) |
UY (1) | UY32308A (es) |
WO (1) | WO2010066699A1 (es) |
ZA (1) | ZA201104231B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3027B1 (ar) * | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
CA2871547C (en) | 2012-05-25 | 2021-05-25 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
AU2013346515B2 (en) * | 2012-11-16 | 2017-05-25 | NuCana plc | Process for preparing nucleoside prodrugs |
EP2940031B1 (en) * | 2013-03-08 | 2017-09-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Nucleoside phosphoramidate compounds for use in the treatment of hcv |
CN103848876B (zh) * | 2013-03-25 | 2016-05-11 | 安徽贝克联合制药有限公司 | 一种核苷磷酰胺前药及其制备方法和其应用 |
CN105377868A (zh) | 2013-04-12 | 2016-03-02 | 艾其林医药公司 | 用于治疗hcv的高活性核苷衍生物 |
CN105348342B (zh) * | 2014-09-30 | 2018-09-21 | 南京正大天晴制药有限公司 | 核苷氨基磷酸酯化合物及药物组合物和用途 |
WO2016073756A1 (en) * | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
CN105801646B (zh) * | 2014-12-31 | 2019-08-16 | 浙江大德药业集团有限公司 | 炔基取代的核苷氨基磷酸酯 |
WO2016134053A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
EP3265102A4 (en) | 2015-03-06 | 2018-12-05 | ATEA Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
JP6743135B2 (ja) | 2015-09-02 | 2020-08-19 | アッヴィ・インコーポレイテッド | 抗ウィルス性テトラヒドロフラン誘導体 |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
MY197236A (en) | 2016-09-07 | 2023-06-07 | Atea Pharmaceuticals Inc | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
SG10202012214WA (en) | 2017-02-01 | 2021-01-28 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
DE69332616T2 (de) | 1992-12-29 | 2003-11-06 | Abbott Lab | Hemmer der retroviralen Protease |
US20010021509A1 (en) * | 1997-10-23 | 2001-09-13 | Sathe Ganesh Madhusudan | cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor |
CN103319554A (zh) * | 2002-06-28 | 2013-09-25 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
EP2298783B1 (en) * | 2003-02-19 | 2017-12-06 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections |
EP1628685B1 (en) * | 2003-04-25 | 2010-12-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
JP2008532950A (ja) * | 2005-03-08 | 2008-08-21 | バイオタ サイエンティフィック マネージメント ピーティーワイ リミテッド | 治療薬としての二環式ヌクレオシドおよび二環式ヌクレオチド |
ATE493428T1 (de) | 2006-10-10 | 2011-01-15 | Medivir Ab | Hcv-nukleosidinhibitor |
-
2009
- 2009-12-03 PA PA20098852101A patent/PA8852101A1/es unknown
- 2009-12-07 TW TW098141651A patent/TW201036989A/zh unknown
- 2009-12-07 AR ARP090104736A patent/AR074504A1/es not_active Application Discontinuation
- 2009-12-08 CN CN200980150162.0A patent/CN102256991B/zh not_active Expired - Fee Related
- 2009-12-08 US US13/130,602 patent/US8399429B2/en not_active Expired - Fee Related
- 2009-12-08 EA EA201170780A patent/EA020244B1/ru not_active IP Right Cessation
- 2009-12-08 AU AU2009326125A patent/AU2009326125B2/en not_active Ceased
- 2009-12-08 EP EP09764845.5A patent/EP2373671B1/en not_active Not-in-force
- 2009-12-08 SG SG2011040979A patent/SG171973A1/en unknown
- 2009-12-08 MX MX2011006023A patent/MX2011006023A/es active IP Right Grant
- 2009-12-08 KR KR1020117015453A patent/KR20110104000A/ko not_active Application Discontinuation
- 2009-12-08 UY UY0001032308A patent/UY32308A/es unknown
- 2009-12-08 CA CA2745523A patent/CA2745523C/en not_active Expired - Fee Related
- 2009-12-08 ES ES09764845.5T patent/ES2525007T3/es active Active
- 2009-12-08 AP AP2011005717A patent/AP2011005717A0/xx unknown
- 2009-12-08 WO PCT/EP2009/066562 patent/WO2010066699A1/en active Application Filing
- 2009-12-08 JP JP2011539051A patent/JP5683480B2/ja not_active Expired - Fee Related
- 2009-12-08 BR BRPI0922681A patent/BRPI0922681A2/pt not_active Application Discontinuation
-
2011
- 2011-05-16 IL IL212897A patent/IL212897A/en not_active IP Right Cessation
- 2011-06-07 CL CL2011001364A patent/CL2011001364A1/es unknown
- 2011-06-07 ZA ZA2011/04231A patent/ZA201104231B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA020244B1 (ru) | 2014-09-30 |
MX2011006023A (es) | 2011-06-28 |
US8399429B2 (en) | 2013-03-19 |
IL212897A (en) | 2013-12-31 |
JP2012510980A (ja) | 2012-05-17 |
AR074504A1 (es) | 2011-01-19 |
CA2745523C (en) | 2017-07-04 |
CN102256991B (zh) | 2015-08-12 |
EA201170780A1 (ru) | 2011-12-30 |
TW201036989A (en) | 2010-10-16 |
SG171973A1 (en) | 2011-07-28 |
CA2745523A1 (en) | 2010-06-17 |
CL2011001364A1 (es) | 2011-09-23 |
US20110230436A1 (en) | 2011-09-22 |
PA8852101A1 (es) | 2010-07-27 |
ZA201104231B (en) | 2012-11-28 |
AP2011005717A0 (en) | 2011-06-30 |
IL212897A0 (en) | 2011-07-31 |
JP5683480B2 (ja) | 2015-03-11 |
WO2010066699A1 (en) | 2010-06-17 |
EP2373671B1 (en) | 2014-09-10 |
BRPI0922681A2 (pt) | 2016-01-05 |
AU2009326125B2 (en) | 2015-03-12 |
ES2525007T3 (es) | 2014-12-17 |
CN102256991A (zh) | 2011-11-23 |
EP2373671A1 (en) | 2011-10-12 |
KR20110104000A (ko) | 2011-09-21 |
AU2009326125A1 (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32308A (es) | Nucleótidos uracil ciclopropílicos | |
CO6440533A2 (es) | Nucleósidos espiro oxetánicos uracílicos | |
CO6321255A2 (es) | "inhibidores de ciclopropil polimerasa" | |
UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
ECSP109932A (es) | Compuestos de biciclolactama sustituida | |
UY32759A (es) | Inhibidores del virus de la hepatitis c | |
CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
AR082968A1 (es) | Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto | |
AR072803A1 (es) | Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes | |
AR080249A1 (es) | Compuestos en calidad de antagonistas de bradiquinina-b1 | |
BR112017007784A2 (pt) | aperfeiçoamentos em ou relacionados a compostos orgânicos | |
AR073037A1 (es) | Derivados de enfumafungina, utiles en la inhibicionde (1,3)-beta-d-glucano sintasa | |
AR088414A1 (es) | Derivados sustituidos de indol | |
AR085542A1 (es) | Compuestos de azaespirodecanona como inhibidores de hsl | |
AR079267A1 (es) | Derivados del tipo hexahidrociclopenta(b)pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR074514A1 (es) | Derivados de morfina-6-glucuronido, su preparacion y su aplicacion en terapeutica | |
AR068875A1 (es) | Derivados de 4-5-dihidro-5-oxo-imidazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como inhibidores de receptores de npy y2 no peptidicos, para el tratamiento de trastornos de ansiedad , depresion, trastornos metabolicos y endocrinos. | |
AR112803A2 (es) | Derivados de piperazina como moduladores de piruvato quinasa m2 (pkm2) | |
AR079265A1 (es) | Derivados de azabiciclo(3.1.0)hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
TH112183B (th) | สารยับยั้งไซโคลโพรพิล พอลิเมอเรส | |
UY31262A1 (es) | Compuestos de biciclolactama sustituida | |
CO6280059A1 (es) | Nuevos derivados de azabiciclos (3.2.0) hept-3-ilo su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
UY32895A (es) | Derivados acetilénicos de 5-fenilpirazolopiridina, su preparación y su aplicación terapéutica | |
CO6382159A2 (es) | Derivados bicíclicos de morfina-6-glucurónido, su preparación y su aplicación en terapéuticaqq | |
CU20100017A7 (es) | Compuestos de biciclolactama sustituida |